ATM, the protein kinase mutated in the rare human disease ataxia telangiectasia (A-T), has been the focus of intense scrutiny over the past two decades. Initially this was because of the unusual radiosensitive phenotype of cells from A-T patients, and latterly because investigating ATM signalling has yielded valuable insights into the DNA damage response, redox signalling and cancer. With the recent explosion in genomic data, ATM alterations have been revealed both in the germline as a predisposing factor for cancer and as somatic changes in tumours themselves. Here we review these findings, as well as advances in the understanding of ATM signalling mechanisms in cancer and ATM inhibition as a strategy for cancer treatment.
INTRODUCTION
ATM, the gene mutated in ataxia telangiectasia (A-T), has been associated with cancer since its discovery, because A-T patients are prone to thymic lymphoma and other cancers. 1 The first explanation for this predisposition was that ATM encodes a kinase central to the repair of double-strand breaks (DSBs) in DNA, thereby controlling genome stability and cell survival (reviewed in Shiloh 2 ). A-T cells show radioresistant DNA synthesis-failure to stop or slow cell-cycle progression in response to radiation damage-revealing a lack of checkpoint control that clearly contributes to cancer predisposition. However, this is just one aspect of ATM's function. Over recent years, a wealth of evidence has accumulated showing that ATM is part of many other signalling networks, including cell metabolism and growth, oxidative stress, and chromatin remodelling, all of which can affect cancer progression. These diverse effects mean that the predisposition to cancer of various types, and its clinical course in each case, is altered by inherited and spontaneous ATM mutations.
Although ATM is rightly considered to be a tumour suppressor, ATM signalling can also be advantageous to cancer cells, particularly in resistance to radio-and chemotherapeutic treatment. For this reason, ATM inhibitors have been developed for use in cancer therapy. Here we will review these apparently paradoxical ATM functions with reference to ATM signalling in cancer cell and mouse models as well as human patients.
ATM-a multifunctional kinase
The ATM protein is a very large, 370 kDa kinase encoded on human chromosome 11q22-23. Mouse ATM, encoded on chromosome 9, is 84% identical to the human protein, and homologs have been found in all eukaryotes. Because of its size, a detailed atomic structure of the whole protein has not yet been determined, but a combination of extensive mapping of patient mutations, in vitro studies and comparison with related phosphatidylinositol-like superfamily proteins has resulted in a welldefined domain structure incorporating many post-translational modification sites ( Figure 1 ). As well as a PI3K-like serine/threonine kinase, which is flanked by FAT (named after the FRAP, ATR and TRRAP proteins) and FATC domains at the C terminus, the protein also contains N-terminal HEAT repeats (named after the proteins huntingtin, elongation factor 3, the A subunit of PP2A and TOR1) and a substrate-binding domain. The kinase domain is responsible for several autophosphorylations, as well as phosphorylating the hundreds of ATM substrates identified so far. 3 The high number of targets and extensive potential for modulation places ATM as a signalling hub, with many different inputs and a complex output subject to the actions of cofactors, substrates and feedback regulation.
ATM SIGNALLING ATM signalling can be broadly divided into two categories: a canonical pathway, which signals together with the Mre11-Rad50-NBS1 (MRN) complex from DSBs and activates the DNA damage checkpoint, and several non-canonical modes of activation, which are activated by other forms of cellular stress ( Figure 2 ). Both signalling categories are likely to contribute to ATM's role in tumour suppression.
can still phosphorylate the histone H2AX in response to DSBs. 10 This argues that autophosphorylation is separable from ATM dimer dissociation and activity in some situations. In support of this idea, ATM mutants lacking autophosphorylation sites are functional, 11, 12 though phosphorylation at Ser1981 may be necessary for retention of ATM at DSB sites. [13] [14] [15] Activated ATM phosphorylates H2AX, enabling the recruitment of DNA repair complexes visible by immunofluorescence as nuclear foci. 16 ATM-dependent phosphorylation of Mdc1 also recruits RNF8 and consequently RNF168 ubiquitin ligases to damage sites. [17] [18] [19] RNF168 monoubiquitylates histones H2A and H2AX on lysines 13 and 15 and primes them for polyubiquitylation, necessary for recruitment of further repair factors. 20 ATM and Mdc1 determine the spreading of gH2AX along chromatin, while ubiquitin enzymes control spreading of ubiquitylated histones. 21, 22 Continued ATM activation is required to maintain damage foci even when ubiquitylated regions are expanded. 22 A complex feedback system dynamically tunes ATM signalling to the existing damage-as long as damage persists above a threshold, ATM is activated in a pulse-like manner due to feedback from activated p53. 23 The molecular details of ATM signalling at DSBs have been extensively reviewed. [24] [25] [26] Here we will highlight the emerging interplay between ATM and chromatin in this response.
Many groups have shown that ATM is important for the repair of DSBs at diverse genome locations, including euchromatic immunoglobulin loci, 15, 27, 28 while others have found that it is particularly required for DSBs located in heterochromatin. 29, 30 Although experiments with laser lines show a local decondensation of chromatin at DSBs that is ATM-independent, 9 ATM also decondenses chromatin to increase accessibility to repair machinery and reinforce its own activation. ATM-dependent phosphorylation of RNF20/RNF40 leads to ubiquitination of histone H2B, and ATM phosphorylation of Kap1 reduces its affinity for the chromodomain protein CHD3, both of which lead to decompaction of chromatin structure. [31] [32] [33] Chromatin relaxation at DSB sites also ensures efficient ATM activation. It has long been known that histone deacetylase inhibitors activate ATM, 4 and Tip60 mediates acetylation of histones H4 and H2AX to remodel chromatin at DSB sites. 34 DMAP1, a member of the Tip60 histone acetyltransferase complex, is required for H4K16 acetylation and ATM activation in response to DNA damage. 35 The nucleosome-binding protein HMGN1 increases H3K14 acetylation, also loosening chromatin structure. This allows a threefold increase in chromatin-bound ATM in response to DSBs. 36 Activation of ATM in response to UV damage is also enhanced by chromatin decompaction: the NER protein XPC recruits the chromatin remodelling complex SWI/SNF, which in turn increases ATM recruitment. 37 Conversely, ATM also mediates transcriptional silencing, associated with chromatin compaction, at chromosome regions spreading several kilobases from a DSB. 38, 39 Histone H2A K119 monoubiquitination, required for silencing, is partly ATM dependent and occurs via the E3 ubiquitin ligase Bmi1. [39] [40] [41] RNF168-mediated ubiquitylation of histone H2A K13-15 also affects the extent of silencing. 22 This mechanism is likely to be 190 and Aurora B phosphorylates serine 1403 in mitosis. 191 In oxidising conditions, cysteine 2991 forms a disulphide linkage with a second ATM molecule to form a dimer. 68 The N-terminal portion interacts with substrates and cofactors such as NBS1, p53, BRCA1, LKB1 and BLM; amino acids 91-97 (here shown in purple) are required for IR-induced formation of nuclear ATM foci. 192 Also in the N-terminal portion are a proposed chromatininteraction domain, a nuclear localisation sequence (NLS), two caspase 3 cleavage sites, and a putative leucine zipper region. [193] [194] [195] The majority of the protein is composed of 49 HEAT repeats (named after the proteins huntingtin, elongation factor 3, the A subunit of PP2A and TOR1). 196 These likely mean that ATM is highly flexible; indeed, a low-resolution structural study of ATM found a flexible arm region that changes conformation upon DNA binding. 197 Diagram produced using Domain Graph 2.0. ATM signals together with the MRN complex at DSBs (canonical pathway, left); together with ATMIN following non-DSB stimuli such as oxidative stress and chromatin changes (middle) and can also form disulphide dimers in oxidative stress conditions (right). Chromatin remodelling around DSBs also contributes to canonical ATM activation. The MRN subunit NBS1 and ATMIN bind competitively to ATM, 47 but the relationship between the redox dimer and the other pathways is unknown. For simplicity, only a subset of key ATM substrates is shown. See text for details.
relevant mainly in euchromatic regions, and so would not conflict with ATM-mediated opening of heterochromatin. 42 A similar silencing process involving the related kinase ATR (ATM and Rad3-related) occurs during spermatogenesis. 43 Non-canonical ATM signalling ATM signalling via ATMIN. Interestingly, ATM is also activated by chromatin changes alone, in the absence of detectable DNA damage. Cell culture treatments such as chloroquine and hypotonic stress activate ATM and cause phosphorylation of downstream targets, such as p53 and Kap1. 4 Importantly, NBS1 is not required for ATM activation by these stimuli, 44 suggesting that there is a second, non-canonical pathway of ATM activation. ATMIN (also called ASCIZ) was identified as an ATM substrate and modulator of DNA repair 45 and subsequently revealed as an ATM interactor required for ATM signalling in response to chloroquine and hypotonic stress ( Figure 2 ). 46 Recent work has shown that ATMIN binds to ATM using a motif homologous to the ATM interaction motif of NBS1 and that ATMIN competes with NBS1 for ATM. 47 ATMIN is not required for IR-induced ATM signalling, and physiologically relevant stimuli triggering ATM signalling via ATMIN are still elusive. However, phosphorylation of ATM targets in response to reactive oxygen species (ROS) partly requires ATMIN, and ATMIN-deficient murine embryonic fibroblasts (MEFs) are more sensitive to atmospheric oxygen than wild-type MEFs. 48 ATMIN signalling in genome stability and cancer. The importance of ATMIN for genome stability is demonstrated by the aberrant chromosomal translocations and lymphoma development seen in mice with ATMIN-deficient B cells. 49 ATMIN-deficient B cells contain aberrant translocations similar to those in ATM-deficient cells, and ATMIN deficiency does not further impair class switch recombination in cells treated with ATM inhibitor, suggesting that the ATMIN-null phenotype occurs, at least in part, through defective ATM signalling. Unusually, correct recombination of immunoglobulin genes following DSB induction requires both ATMIN and NBS1, indicating that both canonical and noncanonical ATM signalling is required.
The timing of ATMIN deletion is important: B-cell lymphomas develop when the CD19-cre line is used but not when ATMIN is deleted earlier in haematopoietic stem cells using the Vav2 promoter (Loizou et al. 49 and unpublished data). Consistent with this, Heierhorst and colleagues used Mb-1-cre to delete ATMIN from the early pro-B-cell stage and found B-cell lymphopenia but no lymphomas. This earlier defect was caused by impaired cell survival due to aberrant transcriptional regulation of Dynll1.
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The ATMIN-null mouse is embryonic lethal, 48,51 though it is not known whether aberrant transcription contributes to this phenotype. At present, it is unclear how the transcriptional role of ATMIN integrates with ATM signalling.
ATM signalling in replication stress and cross-talk with ATR. The DNA damage response from replication stress and excess singlestranded DNA is mainly associated with the ATR kinase, not ATM. In certain instances, however, the ATM and ATR arms of the DNA damage response are linked. For example, at DSBs, ATM-dependent extensive resection of the 5 0 strand exposes single-stranded DNA that induces activation of ATR, and there is a clear switch between the two kinases depending on the length of the overhang. 52 Conversely, some ATM signalling depends on previous activation of ATR. For example, treatment of cells with IR induces ATRdependent ATM phosphorylation in neighbouring 'bystander' cells that receive soluble distress signals. 53 UV irradiation induces replication fork stalling and ATR-dependent activation of ATM. 54, 55 More recent studies have suggested that ATM activation following replication fork stalling is due to replication fork collapse and DSB formation, when lesions are encountered by the replication machinery in S phase. 56, 57 However, if DSBs were the sole trigger, we would expect more ATM activation in ATR-deficient cells due to increased fork collapse and DSB formation, yet ATM signalling after UV is reduced. 55 It is therefore likely that some ATM signalling occurs specifically in response to replication stress and ATR activation and is not just stimulated by DSBs.
Currently, however, it is unclear exactly what triggers ATM signalling in replication stress conditions. Replication stress induced by DNA interstrand crosslinks activates ATM via the WRN helicase, 58 and ATM-dependent phosphorylation of WRN is important for the recovery of collapsed replication forks. Interestingly, relocalisation of WRN into nuclear foci following replication stress requires phosphorylation by ATR, 59 supporting the idea that ATR may be a prerequisite for ATM activation at stalled forks.
Other forms of replication stress have been shown to activate ATM independently of ATR. For example, nuclear bodies containing 53BP1 form at some fragile sites after replication, in an ATMdependent manner that does not require ATR. 60 ATM is required for replication-coupled repair and viability following thymidine block, and phosphorylation of ATM is required for Ras-induced replicative senescence. 61, 62 Oncogene-induced stress was reported to induce a limited ATM checkpoint response, insufficient to prevent progress into M phase. 63 Recently, ATM has been found to interact with proliferating cell nuclear antigen and stimulate DNA Pol delta activity in untreated cells, possibly facilitating replication associated with homologous recombination or gap repair. 64 Importantly, this function of ATM was only revealed with the use of an ATM inhibitor, and not in cells depleted of ATM, though the reason for this discrepancy is not yet clear.
ATM at telomeres. Chromosome ends normally exist within specialised telomere structures consisting of looped DNA and a protein complex, shelterin, to prevent them from being recognised as DSBs. DNA damage response proteins such as ATM are recruited to telomeres but are inhibited by the shelterin complex. 65 The shelterin subunit TRF2 inhibits ATM in two ways: by directly inhibiting its activation, and by inhibiting the propagation of the ATM signal. 66 Telomere dysfunction, either from lack of ATM or from inappropriate ATM activation at uncapped telomeres, results in chromosome fusions and hence genome instability, increasing the scope for malignancy. 67 ATM as a redox sensor. A separate pathway of ATM activation occurs through dimer oxidation. Instead of dissociating, disulphide bonds form between cysteine residues, resulting in an active dimeric form capable of phosphorylating a subset of ATM substrates. Oxidation results from exposure to atmospheric levels of oxygen, or ROS such as those produced by hydrogen peroxide, and activates ATM directly without the need for MRN 68 ( Figure 2 ). The C2991L point mutant of ATM, which is unable to form the disulphide dimer, is able to respond to DNA damage but not to ROS. 68 The activated ATM dimer is also phosphorylated at Ser1981, but as with the monomer, this modification is not required for phosphorylation of downstream substrates, including p53 Ser18 (Ser15 in mice) and Chk2 Thr68. 68 ROS-activated ATM activates TSC2 via phosphorylation of LKB1 and AMPK, and this inhibits mTORC (mammalian target of rapamycin complex) signalling, thereby decreasing ROS levels. 69 Thus ATM is a redox regulator that reduces oxidative stress. In support of this, ATM-deficient mice show elevated ROS, and A-T cells are more prone to apoptosis when exposed to further oxidative stress. 70, 71 Disregulated redox signalling is an important contributor to the A-T phenotype: lymphoma development in ATM-deficient mice is precipitated by elevated ROS and can be rescued by administering antioxidants. 70 Similarly, decreased ATM function is associated with insulin resistance 72 and antioxidants can rescue this phenotype, 73 arguing that increased ROS, as well as the decreased phosphorylation of ATM targets such as Akt Ser473 and p53 Ser18, contributes to metabolic stress in ATMdeficient animals.
Cementing its position as a redox sensor, ATM is also activated by hypoxia independently of ROS. 74 Hypoxia induces ATM phosphorylation of the transcription factor HIF1 alpha, which stabilises the protein and leads to inhibition of mTORC1 signalling via REDD1. 75 This activation of ATM occurs in a diffuse manner in the nucleus, independently of DSB formation. 74, 75 It is unclear whether the active ATM in this case is the oxidised disulphide dimer described by Guo et al., 68 or a different form. Interestingly, a diffuse pattern of nuclear phospho-ATM staining is also seen in p16-or p21-induced cellular senescence. 76 Prolonged ATM signalling via Chk2 is required for the production of senescenceassociated secretory phenotype cytokines, which in turn boost the DNA damage response. 77, 78 It is thus possible that redox activation of ATM may enhance the response to other forms of damage. Because conditions in solid tumours involve both hypoxia and elevated ROS, ATM signalling may in fact reduce oxidative stress and promote cell survival in some tumours, in addition to its welldocumented tumour-suppressive function in promoting genome stability.
ATM and transcription. Activation of ATM leads to an extensive programme of transcriptional changes, many of which rely on the stabilisation and activation of p53. 79 As well as this nuclear pathway, ATM also activates transcription through a pathway involving nuclear-cytoplasmic shuttling and nuclear factor (NF)-kB. In response to IR, ATM phosphorylates NEMO and shuttles to the cytoplasm to activate inhibitor-kB kinase and hence NF-kB. 80 At the same time, ATM promotes NF-kB activation via ubiquitylation of NEMO and ELKS. 81, 82 NEMO sumoylation also promotes NF-kB activation, and a negative feedback loop involving ATMdependent expression of the SUMO protease SENP2 leads to desumoylation and inhibition of NF-kB signalling. 83, 84 Interestingly, the outcome of NF-kB signalling appears to be different depending on the type of stress encountered. Wu and Miyamoto 85 found that replication stress tended to promote apoptosis, whereas signalling induced by DSBs favoured cell survival, despite both stimuli using an ATM-dependent pathway for NF-kB activation. It is possible that different forms of ATM may be involved depending on the stimulus; at present, it is unclear whether NF-kB signalling is activated by an autophosphorylated ATM monomer as in the canonical signalling pathway, the disulphide-linked oxidised dimer, or another ATM active form.
ATM-DEFICIENT MOUSE MODELS
ATM's response to cellular stresses such as DNA damage and ROS acts to limit the proliferation of aberrant cells and protect cells from conditions that can lead to tumourigenesis. ATM-null mice develop T-cell lymphomas with high penetrance due to defective V(D)J recombination, [86] [87] [88] [89] and loss of ATM doubles the incidence of intestinal tumours in APC mutants. 90 Notably, although patients with mutations in NBS1 frequently develop lymphoid malignancies, NBS1-deficient mice, or mice expressing a humanised mutant NBS1 allele found in Nijmegen breakage syndrome patients, do not. 44, 91 This suggests that NBS1 is not required for ATM's tumour-suppressive function in mice.
The development of B-cell lymphomas in conditional ATMINdeficient mouse models points towards a tumour-suppressive role for non-canonical ATM signalling, but the lethality of the ATMINnull mouse means that more conditional models will be needed to investigate this role further. As ATM-null mice are viable, it is possible that the embryonic lethal phenotype of ATMIN-deficient mice reflects an ATM-independent function of ATMIN. Alternatively, disrupting the balance between ATMIN-and NBS1-dependent ATM signalling may be more deleterious than removing ATM completely: deletion of NBS1 is also lethal in MEFs, but cell viability is restored by concomitant deletion of ATMIN. 47 Interestingly, the ATM kinase-dead mouse is also embryonic lethal, 92, 93 indicating that inactive ATM is deleterious during embryogenesis. Conceivably, the ATM kinase-dead and ATMIN-null embryonic lethal phenotypes could be related (if, for example, both result in inappropriately localised ATM protein), but at present there is no evidence to link these two phenotypes.
The reason for the lethality of kinase-dead ATM is not yet understood, particularly because both initial studies indicated that the inactive protein is not a classical dominant negative, 92, 93 and its effect on tumourigenesis remains to be explored. However, the notion that mutant ATM can be worse than no ATM is supported by the increased tumour development in mice heterozygous for the human 7636del9 ATM mutation (7636del9/ þ ) compared with germline ATM þ / À heterozygotes 94 and increased genome instability in ATM kinase-dead/ À heterozygotes compared with ATM null cells. 93 ATM also shows haploinsufficiency in tumour suppression: ATM heterozygosity increases the incidence of mammary carcinomas in TP53 heterozygote mice. 95 p53 deficiency accelerates tumourigenesis in ATM-null mice, as well as expanding the type of malignancies to sarcomas and B-cell as well as T-cell lymphomas. 96 The p53 Ser18Ala mutation shows some embryonic lethality in combination with ATM deficiency, and the remaining mice develop T-cell lymphomas.
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Cdc20 deficiency accelerates thymic lymphomagenesis in ATMnull mice, 98 whereas p21 and WIP1 deficiencies delay it.
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Interestingly, RNF8/Chfr double knockout mice, which lack the ubiquitin ligases that control chromatin relaxation via H4K16 acetylation, develop thymic lymphomas similar to ATM-null mice, suggesting a similar defect in DSB repair. 101 In the absence of ATM, mice become more reliant on other repair proteins: ATM/PARP1 (poly ADP-ribose polymerase 1) and ATM/H2AX double knockout mice are embryonic lethal. 102, 103 This synthetic lethality could be exploited for cancer therapy, either by inhibiting repair in ATM-deficient cells or by combining ATM inhibitors with other DNA-damaging agents. This will be discussed further under 'ATM signalling in human cancer and therapy'.
ATM SIGNALLING IN CANCER CELLS
The main tumour-suppressive effects of ATM signalling in cancer cells are the induction of cell-cycle arrest and apoptosis. ATM phosphorylates human DBC1 (deleted in breast cancer) and promotes apoptosis via SIRT1 and p53. 104 ATM also phosphorylates PIDD and promotes apoptosis via RAIDD binding and activation of caspase 2.
105 ATM and Chk1-dependent cellcycle arrest and apoptosis can be induced by curcumin in pancreatic cancer cells. 106 Other agents such as the antibiotic Asperlin and the proteasome inhibitor bortezomib induce cellcycle arrest by activating ATM in a ROS-dependent manner. 107, 108 To escape from these effects of ATM activation, cancer cells can downregulate ATM expression. For example, the microRNA miR18a downregulates ATM expression and is itself upregulated in breast cancer. 109 Cells may also reduce ATM activity by upregulating WIP1 phosphatase, which dephosphorylates ATM and its substrates, such as p53. 110 Knockdown of WIP1 restores cisplatin sensitivity in oral cancer cells, 111 indicating that ATM signalling can promote cell death in response to chemotherapy.
Perhaps surprisingly, ATM signalling is more frequently upregulated than downregulated in some cancer cells, presumably in those that have already evaded cell-cycle arrest and apoptosis by other means. For example, melanoma cells enhance ATM signalling by overexpression of MAGE-C2, which binds to Kap1 and increases its phosphorylation at Ser824. 112 Prostate cancer cells increase ATM expression by recruiting Ack1-phosphorylated androgen receptor to the ATM gene enhancer, 113 and pancreatic cancer cells overexpress the transcription factor CUX1, which increases ATM expression. 114, 115 Another explanation for increased ATM signalling in tumours could be that oncogene activation in precancerous lesions causes replication stress, which activates the DNA damage response, including ATM, as a barrier to tumourigenesis, and thus ATM signalling may remain active in malignant tumours once it has been uncoupled from cell-cycle arrest and apoptosis. [116] [117] [118] The benefits of ATM signalling for cancer cells include promotion of chemoresistance, radioresistance, metastasis and cell survival. Chemoresistance may arise from ATM signalling via increased expression of the crosslinking enzyme transglutaminase 2, 119 activation of p38 MAPK 120 or overexpression of HMGA proteins, which themselves transcriptionally activate ATM expression. 121 Radioresistance, as seen in a subpopulation of breast cancer cells, 122 simply reflects the increased capacity to deal with DSBs in cells with upregulated ATM signalling. As many chemotherapeutic drugs act by inducing DSBs, radioresistant cells are also frequently resistant to chemotherapy. ATM signalling promotes metastasis through NF-kB-mediated secretion of protumourigenic cytokines, which induce an epithelial-mesenchymal transition (EMT) and promote invasive behaviour. 123 Activation of Akt by ATM also promotes cell survival in certain contexts. 124 Other oncogenic effects of ATM signalling include the upregulation of integrin alphavbeta3, which impairs the immune response to the tumour. 125 In other cases, increased ATM signalling has been correlated with metastatic and invasive behaviour in cancer cells overexpressing HOXB9 (40% of breast cancers 126 ) or underexpressing HtrA1 (PRSS11), both associated with EMT-like changes. 127, 128 Increased ATM expression is also associated with metastasis and decreased patient survival in neuroendocrine cancer. 129 Although not directly linked to metastasis in these cases, hyperactive ATM increases the damage response and therefore promotes chemoand radioresistance in these cells.
ATM signalling and cancer metabolism
The metabolism of tumours is almost always deregulated, consistent with the restricted access to oxygen and nutrients in rapidly proliferating cells. Because ATM deficiency impairs glucose metabolism in humans and mice, [130] [131] [132] the ATM status of cancer cells is important in determining both the altered metabolic state and the response to external metabolic stresses, which affects the survival of cells within the tumour. ATM signalling activates the pentose phosphate pathway in response to oxidative stress, which could support biosynthesis in cancer cells that have switched to a glycolytic metabolism. 133, 134 Conversely, reduced ATM signalling in solid tumours may contribute to survival by promoting autophagy in the context of glucose restriction. 135 Loss of ATM results in an increase in aberrant mitochondria in thymocytes, and rescuing mitochondrial abnormalities by deletion of the autophagy regulator Becn1 delays tumourigenesis in ATM-null mice. 136 As this rescue did not affect the DNA damage response, this study definitively shows that non-canonical ATM signalling contributes to tumour suppression, independently of the documented effects of oxidative stress on DNA repair. 137, 138 Non-canonical ATM activation using low-dose chloroquine also improved the metabolic profile in a mouse model of atherosclerosis, further highlighting ATM's role in processes not involving exogenous DNA damage. 131 
ATM SIGNALLING IN HUMAN CANCER AND THERAPY ATM alterations in human cancer
Germline ATM mutations predispose to cancer. Different ATM mutations have distinct, and sometimes opposing, effects on different pathways, leading to a wide variation in phenotypes. 139 The increased incidence of breast cancer in families of those with A-T has been known for 25 years, 140 but the full picture of mutations responsible and their incidence and penetrance is only now emerging. A-T patients with no detectable ATM kinase activity almost all develop lymphomas in childhood, while those with residual kinase activity survive longer but have a 30-fold increased rate of breast cancer. 141 Patients with Nijmegen breakage syndrome, who have mutations in the MRN subunit NBS1, also have defective ATM activation and are predisposed to cancer, while mutations in the MRN subunit Mre11 cause the rare A-T-like disorder, with a similar genome instability phenotype to A-T but no clear cancer predisposition. 142, 143 Heterozygous ATM mutations, which may be present in as many as 1% of the population, are associated with a fivefold higher risk of breast cancer in those under 50 years of age. 144 The known ATM mutations responsible for the increased susceptibility to breast cancer have been described and catalogued. 145, 146 Some of these are highly penetrant; for example, the germline ATM missense mutation 7271 T-G has a penetrance similar to BRCA2 mutations with regard to breast cancer. 147 In addition to breast cancer, ATM was recently implicated as a susceptibility gene in a case of familial pancreatic ductal adenocarcinoma, with a heterozygous germline mutation coupled with loss of heterozygosity in the tumour. 148 Somatic ATM mutations in tumours. ATM-inactivating mutations, deletions and expression changes have also been found in tumours themselves (Table 1) . ATM point mutations or deletions are the most common anomalies found in chronic lymphocytic leukaemia patients at presentation (approximately 25%) and are associated with poor outcome. 149, 150 Of those patients, 36% have mutations in the remaining ATM allele. The combination of 11q deletion and ATM mutation is associated with significantly shorter progression-free and overall survival of chronic lymphocytic leukaemia patients compared with monoallelic ATM loss or mutation. 151 In wider large-scale studies including solid tumours, B5% of cancers showed ATM aberrations (either mutation or loss). 82, 152 In lung cancers in particular, 8% showed ATM mutations and these were largely mutually exclusive with TP53 mutations. 153 In line with ATM mutations predisposing to breast cancer, ATM was downregulated in 55% of 119 breast tumours compared with adjacent tissue. 154 One study found that ATM was particularly downregulated in solid tumours with areas of hypoxia and another that ATM loss promotes radiation resistance in gliomas, clues to the multiple cell stresses linked to ATM signalling. 75, 155 More recently, ATM alterations have been found in colon cancer. ATM mutations are found in both chromosomally unstable and microsatellite-unstable tumours. 156 In mice, chromosomal instability from spindle checkpoint mutations cooperates with ATM deficiency to accelerate tumourigenesis. 98 It is also possible that the microsatellite instability phenotype may be linked to defective ATM, as recent studies proposed a role for ATM in facilitating replication-associated repair in fragile regions. 60, 64 ATM was the gene that most frequently showed hypermethylation in colorectal carcinomas compared with adenomas, although this was not correlated with differential ATM expression. 157 Modulation of ATM signalling as therapy Because activation of the DNA damage response in tumours can enable them to resist treatment with DNA-damaging agents, damage response pathways have attracted attention as targets for cancer therapy. 158 The DNA damage response becomes beneficial to tumour cells once they have disabled its tumour-suppressive function, for example by mutating a key factor, such as p53. 118 The path of tumour progression and response to treatment depends on both ATM and p53 status. 159, 160 For example, ATM and ATR checkpoint signalling is necessary for the survival of p53-deficient cells after DNA damage, 161 whereas in cancers that have not lost p53, inactivating ATM allows the survival of genomically unstable cells and induces chemoresistance. 159, 162 In tumours that are sensitive to it, ATM inhibition may have a greater effect than ATM loss: ATM inhibitors disrupt sister chromatid exchange in cells with functional ATM, whereas in A-T cells sister chromatid exchange is normal. 163 ATM inhibitors have thus been tested for anticancer activity.
Radiosensitisation. In line with the radiosensitivity phenotype of A-T cells, the primary tests of ATM inhibitors have been in combination with irradiation of cancer cells. Already several generations of ATM inhibitors have been shown to be effective as radiosensitisers in vitro: KU55933; 164 CP466722; 165 and KU60019, with an effect 10 times more potent than KU55933 on glioma cells. 166 KU60019 also inhibits Akt pro-survival signalling and reduces cell motility and invasion. 166 ATM inhibitor was most lethal when given shortly after irradiation treatment. 167 Promisingly, ATM inhibition also showed selectivity: increasing the killing of irradiated cells but protecting adjacent bystander cells, 168 and preferentially sensitising cervical cancer cells over untransformed controls. 169 Cooperation with other therapies. As well as radiation, ATM inhibitors also sensitise cells to reoxygenation after hypoxia, though it is unclear whether this relates to ATM's role as a dimeric redox regulator or its canonical active monomer form following oxidative damage to DNA. 170 Recent research has also tested the effects of ATM inhibitors in combination with other treatments. Fanconi anaemia-deficient pancreatic cancer cells are hypersensitive to ATM inhibition, 171 thus raising the possibility of a synthetic lethal approach to therapy. For example, ATM deficiency sensitises lymphoma cells to PARP inhibitors, 172 consistent with previous work showing that ATM is required for homologous recombination repair in PARP inhibitor-treated cells. 173 ATM inhibition and p53 activation by Nutlin-3 leads to apoptosis in cell lines, 174 while ATM inhibition and Akt inhibition by rapamycin leads to apoptosis in cancer cells with overactive Akt.
124 BRCA1-deficient tumour cells may become sensitive to ATM inhibition if they inactivate 53BP1, a characteristic of resistance to PARP inhibitors. 175 Thus, ATM inhibitors could become useful as part of a second line of defence subsequent to initial treatment, as well as in combination with other drugs.
The relationship between ATM and ATR could also be exploited, as ATR inhibition is synthetic lethal with ATM deficiency 176 and the ATM inhibitor KU60019 cooperates with the replication stress-inducing agent temozolomide to reduce glioblastoma cell proliferation. 177 The ATM inhibitor KU59403 has recently undergone preclinical testing in mice, in combination with topoisomerase poisons such as camptothecin. 178 However, at present, there are no reports of ATM inhibitors in use in clinical trials, though this situation is likely to change as suitable patient populations are identified.
Therapies activating ATM?
In keeping with its function as a tumour suppressor and ability to promote cell-cycle arrest or apoptosis, re-activation of ATM could also be useful as a cancer therapy in tumours where it has been downregulated. The chemotherapy drug doxorubicin activates ATM via the production of superoxide radicals and induces apoptosis via p53. 179 In addition, ATM's ability to relax chromatin may be beneficial. Cancer cells can become drug resistant by globally compacting their chromatin via insulin-like growth factor 1 receptor signalling and histone demethylation. 180 Histone deacetylase inhibitors activate ATM 4 and could be used as therapeutic agents to relax chromatin and hence re-sensitise cells to DNA-damaging drugs. 181 ATM deficiency has been shown to sensitise cells to PARP inhibition. 172 Conversely, abnormally active ATM, as seen when phosphatases such as PPP2R2A are blocked, also impairs DNA repair by homologous recombination and thereby sensitises cells to PARP inhibition.
14 Thus, timely activation and inactivation of ATM are both necessary for efficient repair, and any ATM perturbation could inhibit the ability of cells to resist DNA damage. However, more research is needed to determine the effects of artificial ATM activation on normal tissue.
Interestingly, the diabetes drug metformin activates ATM, and patients who take metformin have a lower risk of developing cancer than other diabetes patients. 182, 183 The reasons for this are still unclear, but it is possible that a heightened DNA damage response, as well as the constitutive lowering of blood glucose and insulin levels, contributes to tumour suppression. Alternatively, Type II diabetes is known to be a risk factor for cancer, 184 and thus metformin may indirectly lower cancer risk by improving the patients' metabolic profile. If this is true, metformin may not have a tumour-suppressive effect in patients who do not have a metabolic disorder. A recent study found a differential effect of metformin on the proliferation of breast cancer cells depending on the insulin responsiveness of the patient. 185 It is also likely that germline variations in ATM, or closely related sequences, will affect the response to metformin in cancer as they do in diabetes. 186 Nevertheless, the potential benefits of this 199 Note that COSMIC data might underestimate the true scale of ATM aberrations in cancer, as it is restricted to somatic mutations and does not include changes in gene expression or copy number. In addition, the database includes benign neoplasms, while the samples used in the individual studies quoted were selected exclusively from patients with malignant cancer.
long-established drug are substantial, and clinical trials looking at metformin as an anticancer agent are already underway. 187 In cases where ATM deficiency directly contributes to tumourigenesis, restoring ATM function to the tissue could potentially inhibit cancer development. In ATM-deficient mice, transplanting ATM-competent bone marrow-derived cells delayed the onset of thymic lymphoma from around 3 months to over 9 months. 188 If a similar effect occurs in humans, transplant therapy could be a very valuable asset in preventing cancer in A-T patients.
